大B细胞淋巴瘤继发中枢神经系统受累的治疗结局与复发模式
该国际队列研究纳入1139例继发中枢神经系统大B细胞淋巴瘤患者,评估治疗结局与复发模式。2年无进展生存率在初治型、中枢孤立复发型和同步复发型分别为40.4%、43.9%和16.2%。噻替哌自体干细胞移植与更长生存相关,且经倾向评分匹配后优于CAR-T。
要点
- 初治型与中枢孤立复发型SCNSL的2年PFS分别为40.4%和43.9%,同步复发型仅16.2%。
- 中枢孤立复发型24个月累积复发率仅6%,支持采用原发中枢淋巴瘤方案。
- 噻替哌ASCT在初治型和中枢孤立复发型中与更长生存相关,匹配后优于CAR-T。
核心结论
- 数据支持对符合条件的SCNSL患者采用噻替哌ASCT,尤其初治疾病和中枢孤立复发。
- 中枢孤立复发型系统性复发率低,支持采用原发中枢淋巴瘤的治疗方案。
研究设计与样本
- 国际多中心队列研究,共纳入1139例继发中枢神经系统大B细胞淋巴瘤患者。
- 初治型SCNSL 537例,复发型SCNSL 602例。
- 采用竞争风险模型估计累积复发率,6个月界标多变量分析识别预后因素。
- 经倾向评分匹配比较噻替哌ASCT与CAR-T的结局。
主要发现
- 2年PFS在初治型、中枢孤立复发型和同步复发型分别为40.4%、43.9%和16.2%。
- 中枢孤立复发型24个月累积复发率为6%。
临床怎么用
- 对符合条件的SCNSL患者,尤其初治型和中枢孤立复发型,可考虑噻替哌ASCT。
- 中枢孤立复发型系统性复发率低,可采用原发中枢淋巴瘤的治疗方案。
- 同步复发型患者ASCT(含或不含噻替哌)也与生存改善相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes after thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor (CAR) T-cell therapy (CAR-T) delivered at relapse were compared after propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). Two-year PFS estimates were 40.4%, 43.9%, and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse, respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR, 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: hazard ratio [HR], 0.57; P = .005; and OS: HR, 0.62; P = .023) and CNS-isolated relapses (PFS: HR, 0.55; P = .002; and OS: HR, 0.39; P< .0001). ASCT (thiotepa or no thiotepa) also associated with improved survival in synchronous relapses (PFS: HR, 0.57; P = .023; and OS: HR, 0.48; P = .019). Higher survival with thiotepa-ASCT than CAR-T was observed after PSM (PFS: HR, 0.45; P = .005 and OS: HR, 0.41; P = .014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.
引用
- Alderuccio JP, Baggio D, Han S, et al. Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma. Blood. 2026. PMID: 41490516. doi:10.1182/blood.2025031455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。